Skip to main content

Table 2 Hazard Ratios depicting time to buprenorphine discontinuation or censoring

From: Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims

  

aHR

95% CI

Model 1

Substance Use Disorder Facility vs. Outpatient Psychiatry

1.03

1.01

1.06

Outpatient Primary Care vs Outpatient Psychiatry

1.08

1.05

1.10

Model 2

Limited to Medicaid enrollees (adjusting for race/ethnicity)

Substance Use Disorder Facility vs. Outpatient Psychiatry

1.21

1.12

1.30

Outpatient Primary Care vs Outpatient Psychiatry

1.36

1.26

1.47

Model 3

SUD Facility + Medicaid (vs Outpatient Psychiatry + Commercial Insurance)

1.24

1.20

1.29

SUD Facility + Commercial Insurance (vs Outpatient Psychiatry + Commercial Insurance)

1.02

0.99

1.05

Outpatient Primary Care + Medicaid (vs Outpatient Psychiatry + Commercial Insurance)

1.39

1.34

1.45

Outpatient Primary Care + Commercial Insurance (vs Outpatient Psychiatry + Commercial Insurance)

1.04

1.01

1.07

Outpatient Psychiatry + Medicaid (vs Outpatient Psychiatry + Commercial Insurance)

1.03

0.96

1.11

  1. This table illustrates multivariable cox regression models, with aHR representing adjusted hazard ratios. An aHR greater than 1 represents an association of setting type with higher likelihood of discontinuation; an aHR less than 1 represents an association of setting type with lower likelihood of discontinuation; an aHR of precisely 1 would represent no association between setting type and discontinuation
  2. Full Models are shown in the Supplementary Information. Model 1 adjusts for: 1) Male vs Female, 2) Commercial vs Medicaid, 3) Age > 30 vs < 30 years, 4) Co-occurring alcohol use disorder vs no alcohol use disorder, 5) Co-occurring amphetamine use disorder vs no amphetamine use disorder, 6) Co-occurring cocaine use disorder vs no cocaine use disorder, 7) Co-occurring sedative use disorder vs no sedative use disorder, 8) Co-occurring mood disorder vs no mood disorder, 9) Co-occurring anxiety disorder vs no anxiety disorder, 10) Co-occurring psychotic disorder vs no psychotic disorder, 11) Charlson comorbidity index = 1 or 2 vs charlson comorbidity index = 0, 12), charlson comorbidity index = 3 + vs charlson comorbidity index = 0, 13) Drug-related poisoning in the 6 months preceding treatment initiation. Model 2 adjusts for: 1) Male vs Female, 2) Race/Ethnicity (non-Hispanic Black vs White; Hispanic vs White; other/unknown race vs White),, 3) Age > 30 vs < 30 years, 4) Co-occurring alcohol use disorder vs no alcohol use disorder, 5) Co-occurring amphetamine use disorder vs no amphetamine use disorder, 6) Co-occurring cocaine use disorder vs no cocaine use disorder, 7) Co-occurring sedative use disorder vs no sedative use disorder, 8) Co-occurring mood disorder vs no mood disorder, 9) Co-occurring anxiety disorder vs no anxiety disorder, 10) Co-occurring psychotic disorder vs no psychotic disorder, 11) Charlson comorbidity index = 1 or 2 vs charlson comorbidity index = 0, 12), charlson comorbidity index = 3 + vs charlson comorbidity index = 0, 13) Drug-related poisoning in the 6 months preceding treatment initiation. Model 3 adjusts for: 1) Age > 30 vs < 30 years, 2) Co-occurring alcohol use disorder vs no alcohol use disorder, 3) Co-occurring amphetamine use disorder vs no amphetamine use disorder, 4) Co-occurring cocaine use disorder vs no cocaine use disorder, 5) Co-occurring sedative use disorder vs no sedative use disorder, 6) Co-occurring mood disorder vs no mood disorder, 7) Co-occurring anxiety disorder vs no anxiety disorder, 8) Co-occurring psychotic disorder vs no psychotic disorder, 9) Charlson comorbidity index = 1 or 2 vs charlson comorbidity index = 0, 10), charlson comorbidity index = 3 + vs charlson comorbidity index = 0, 11) Drug-related poisoning in the 6 months preceding treatment initiation
Back to article page

Addiction Science & Clinical Practice

ISSN: 1940-0640